Cargando…

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

BACKGROUND: To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials. METHODS: Combined data from 16 phase II studies (N = 529 patients) were analyzed to determine pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levin, Victor A, Ictech, Sandra, Hess, Kenneth R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1919386/ https://www.ncbi.nlm.nih.gov/pubmed/17587447 http://dx.doi.org/10.1186/1471-2407-7-106

Ejemplares similares

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas
por: Levin, Victor A, et al.
Publicado: (2018)

Clinical nomogram for predicting the survival of patients with cerebral anaplastic gliomas
por: Zhao, Ye-Yu, et al.
Publicado: (2020)

Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas
por: Hong, Je Beom, et al.
Publicado: (2020)

Effect of radiation dose to the periventricular zone and subventricular zone on survival in anaplastic gliomas
por: Valiyaveettil, Deepthi, et al.
Publicado: (2019)

P-values, survival analyses and phase II trials.
por: Fayers, P.
Publicado: (1994)

Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review
por: Araujo, Raphael L C, et al.
Publicado: (2017)

Predictors of recurrence free survival for patients with stage II and III colon cancer
por: Tsikitis, Vassiliki L, et al.
Publicado: (2014)

A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
por: Bleehen, N. M., et al.
Publicado: (1995)

The power of phase II end-points for different possible mechanisms of action of an experimental treatment
por: Wason, J.M.S., et al.
Publicado: (2015)

Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
por: Jiménez‐Ubieto, Ana, et al.
Publicado: (2017)

Impact of GAP-43, Cx43 and actin expression on the outcome and overall survival in diffuse and anaplastic gliomas
por: Krigers, Aleksandrs, et al.
Publicado: (2023)

Anaplastic Thyroid Cancer Presenting With Brain Metastasis: 17-year Progression Free Survival
por: Howard, Kathryn Kay, et al.
Publicado: (2021)

Design of Phase II cancer trials evaluating survival probabilities
por: Case, L Douglas, et al.
Publicado: (2003)

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial
por: Fukano, Reiji, et al.
Publicado: (2020)

The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma
por: Burzynski, Stanislaw R., et al.
Publicado: (2014)

Laparoscopic Radiofrequency Fibroid Ablation: Phase II and Phase III Results
por: Galen, Donald I., et al.
Publicado: (2014)

Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
por: Duputel, Benjamin, et al.
Publicado: (2023)

Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial
por: Lepski, Guilherme, et al.
Publicado: (2023)

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
por: Zhang, Yu-An, et al.
Publicado: (2016)

Survival of patients treated with radiation therapy for anaplastic astrocytoma
por: Barker, Christopher A., et al.
Publicado: (2014)

Prognostic factors associated with survival in patients with anaplastic oligodendroglioma
por: Liu, Shuo, et al.
Publicado: (2019)

Nomograms Predict Survival in Patients with Anaplastic Thyroid Carcinoma
por: Qiu, Bei, et al.
Publicado: (2019)

A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer
por: Ljubas, Josip, et al.
Publicado: (2019)

Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
por: Idbaih, Ahmed, et al.
Publicado: (2010)

MON-446 Anaplastic Thyroid Cancer Presenting with Brain Metastasis: 17-Year Progression Free Survival
por: Howard, Kathryn Kay, et al.
Publicado: (2020)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
por: de Klerk, Leonie K, et al.
Publicado: (2021)

The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas
por: Zhou, Jie, et al.
Publicado: (2022)

Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application
por: Karabacak, Mert, et al.
Publicado: (2023)

Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial
por: Catalano, Maria Graziella, et al.
Publicado: (2016)

Identification of Gender- and Subtype-Specific Gene Expression Associated with Patient Survival in Low-Grade and Anaplastic Glioma in Connection with Steroid Signaling
por: Hirtz, Alex, et al.
Publicado: (2022)

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
por: Paoletti, Xavier, et al.
Publicado: (2020)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

The phase of the menstrual cycle has no influence on the disease-free survival of patients with mammary carcinoma.
por: Wobbes, T., et al.
Publicado: (1994)

Survival Benefit of Intervention Treatment in Advanced Anaplastic Thyroid Cancer
por: Kasemsiri, Pornthep, et al.
Publicado: (2021)

Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome
por: Seo, Dong Ok, et al.
Publicado: (2022)

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2022)

Meta-analysis of randomized phase II trials to inform subsequent phase III decisions
por: Burke, Danielle L, et al.
Publicado: (2014)

Using meta-analysis of Phase II trials to predict Phase III trial results
por: Burke, Danielle, et al.
Publicado: (2013)

Using phase II data for the analysis of phase III studies: An application in rare diseases
por: Wandel, Simon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1gh86s47dm0l70jd3se4s86lm0